ARTICLE | Company News
MacroGenics, Synthon deal
December 16, 2016 8:28 PM UTC
Synthon granted MacroGenics rights to duocarmycin-based linker-drug technology to develop and commercialize preclinical MGC018. Synthon will receive license fees and is eligible for milestones and roy...
BCIQ Target Profiles